StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1255.HK$2.11+0.00%
Fair $2.11+0.0%

1255.HK

TATA Health International Holdings Limited

Consumer Cyclical / Footwear & AccessoriesHKSE

$2.11

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $2.11Fund rank 26/100 · Data gapFallback financials|
SA 44/C
F-Score: 5/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-3.6M · quality 46.0/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 14/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

44/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. Revenue has declined for 3 consecutive years ROE is -24.5%, below the 5% threshold
Thesis & Journal · 1255.HKLocal privado en este navegador · TATA Health International Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$512M

P/E

42.2x

↑

EV/EBITDA

18.4x

↑

ROE

-24.5%

↓

Gross Margin

80.4%

↑

Debt/Equity

-0.48

↓
52-Week Range$2
$0$3

TradingView lightweight chart

1255.HK price, volumen y niveles de valoración

Último $2.110Periodo -0.9%
Fair value: $2.110

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2025 · 4 años de histórico normalizado

Revenue CAGR

-11.3%

FCF CAGR

—

FCF margin

-20.8%

FCF / Net income

-1.56x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $99.8M · net income $13.3M · FCF $-20.8M

2021-FY → 2025-FY

Gross margin

80.4%+15.4% pts

Operating margin

-22.9%+13.0% pts

Net margin

13.4%+51.1% pts

FCF margin

-20.8%-17.1% pts
MetricTTM
2025
2024
2022
2021
Income Statement
Revenue$99.8M$99.8M$129.7M$144.6M$160.9M
Net Income$13.3M$13.3M$-68.3M$9.6M$-60.8M
EBITDA$28.3M$28.3M$-48.2M$18.6M$-52.6M
EPS0.050.05-0.280.04-0.26
Gross Margin80.4%80.4%69.5%78.8%65.1%
Operating Margin-22.9%-22.9%-26.9%-18.6%-35.8%
Net Margin13.4%13.4%-52.7%6.6%-37.8%
Balance Sheet
Debt/Equity-0.48-0.48-0.561.522.29
Current Ratio0.500.50———
Cash Flow
Free Cash Flow$-20.8M$-20.8M$-3.6M$12.1M$-6.0M
Returns
ROE-24.5%-24.5%106.0%28.6%-264.1%
Valuation
P/E42.2042.20—18.75—
EV/EBITDA18.3618.36—10.72—
P/B———5.4117.14
Growth & Yield
Revenue Growth-23.0%-23.0%-10.3%-10.1%—
EPS Growth117.9%117.9%-800.0%115.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

55.3%

muy exigente

EPS terminal req.

$0.19

Spread vs growth

62.6%

5Y implied EPS CAGR

35.3%

muy exigente

EPS terminal req.

$0.23

Spread vs growth

82.6%

10Y implied EPS CAGR

22.0%

exigente

EPS terminal req.

$0.36

Spread vs growth

95.9%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +603.3%

Total return

+603.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.28 → 0.05

Residual

+603.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+603.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.